EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

H.R. Hendriks; P.E. Pizao; D.P. Berger; K.L. Kooistra; M.C. Bibby; E. Boven; H.C. Dreef-Van der Meulen; R.E.C. Henrar; H.H. Fiebig; J.A. Double; H.W. Hornstra; H.M. Pinedo; P. Workman; G. Schwartsmann

EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

H.R. Hendriks
, P.E. Pizao
, D.P. Berger
, K.L. Kooistra
, M.C. Bibby
, E. Boven
, H.C. Dreef-Van der Meulen
, R.E.C. Henrar
, H.H. Fiebig
, J.A. Double
, H.W. Hornstra
, H.M. Pinedo
, P. Workman
, G. Schwartsmann

Research output: Contribution to journal › Article › Academic › peer-review

25 Downloads (Pure)

Original language	English
Pages (from-to)	897-906
Journal	European Journal of Cancer
Volume	29A
Issue number	6
Publication status	Published - 1993

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

8487Final published version, 11.1 MB

Cite this

Hendriks, H. R., Pizao, P. E., Berger, D. P., Kooistra, K. L., Bibby, M. C., Boven, E., Dreef-Van der Meulen, H. C., Henrar, R. E. C., Fiebig, H. H., Double, J. A., Hornstra, H. W., Pinedo, H. M., Workman, P., & Schwartsmann, G. (1993). EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. European Journal of Cancer, 29A(6), 897-906.

@article{19214436821c44b8b99b9abd39d3b5f3,

title = "EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models",

author = "H.R. Hendriks and P.E. Pizao and D.P. Berger and K.L. Kooistra and M.C. Bibby and E. Boven and \{Dreef-Van der Meulen\}, H.C. and R.E.C. Henrar and H.H. Fiebig and J.A. Double and H.W. Hornstra and H.M. Pinedo and P. Workman and G. Schwartsmann",

year = "1993",

language = "English",

volume = "29A",

pages = "897--906",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

number = "6",

}

Hendriks, HR, Pizao, PE, Berger, DP, Kooistra, KL, Bibby, MC, Boven, E, Dreef-Van der Meulen, HC, Henrar, REC, Fiebig, HH, Double, JA, Hornstra, HW, Pinedo, HM, Workman, P & Schwartsmann, G 1993, 'EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models', European Journal of Cancer, vol. 29A, no. 6, pp. 897-906.

TY - JOUR

T1 - EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

AU - Hendriks, H.R.

AU - Pizao, P.E.

AU - Berger, D.P.

AU - Kooistra, K.L.

AU - Bibby, M.C.

AU - Boven, E.

AU - Dreef-Van der Meulen, H.C.

AU - Henrar, R.E.C.

AU - Fiebig, H.H.

AU - Double, J.A.

AU - Hornstra, H.W.

AU - Pinedo, H.M.

AU - Workman, P.

AU - Schwartsmann, G.

PY - 1993

Y1 - 1993

M3 - Article

SN - 0959-8049

VL - 29A

SP - 897

EP - 906

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 6

ER -